Fig. 5.

Anti-CCR7 mediates a slight complement-mediated cytotoxicity in CD19 + cells from healthy donors. a Relative median fluorescence intensity (RMFI) in healthy B cells. B cells from healthy donors (n = 6) were analyzed by FCM to discriminate their corresponding CCR7 and CD52 surface density measured as median relative to an appropriate isotype control (IC). Bars represent mean ± standard mean error. The statistical analysis is referred to CCR7. ***p < 0.001. b Frequency histograms showing CCR7 and CD52 in a representative healthy donor. The pattern and intensity of each surface marker is shown in B cells from a representative healthy donor. c Percentage of specific lysis in healthy B cells. PBMC from healthy donors (n = 4) were incubated with different concentrations of anti-CCR7, alemtuzumab (anti-CD52, Alem) or the respective isotype control (IC) in the presence of 25 % of either active or heat-inactivated rabbit complement. Percentage of cell lysis as a result of CDC was determined according to the formula stated in “Materials and methods” by 7-AAD incorporation and FCM analysis in gated CD19 + cells. Each dot, square or triangle represents mean ± standard mean error. All statistical analyses are referred to CCR7. *p < 0.05; **p < 0.01; ***p < 0.001